NCT02582749 - Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

September 14, 2017

Study Completion Date

September 14, 2017

Conditions

Prostate CancerBone MetastasesProstate Neoplasms

Interventions

DRUG

LHRH agonist/antagonist

Treating physician will determine LHRH agonist/antagonist, dosage and route of administration, per package insert, during each 28-day cycle.

DRUG

Bicalutamide

Bicalutamide, 50 mg Oral (PO) will be administered daily in each 28-day cycle.

RADIATION

Radium-223 dichloride

Radium-223 dichloride, 50 kBq (1.35 microcurie) per kg body weight intravenous (IV bolus) every 28 days for 6 injections

Trial Locations (12)

Integrated Medical Professionals, PLLC, Lake Success

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

IU Health Central Indiana Cancer Centers, Indianapolis

University of Michigan Health System, Ann Arbor

Henry Ford Hospital, Detroit

Metro Health Cancer Center, Wyoming

University of Iowa Hopital and Clinics, Iowa City

Clement J. Zablocki VA Medical Center, Milwaukee

Illinois CancerCare, P. C., Peoria

GU Research Network, LLC, Omaha

University of Texas Medical Branch at Galveston, Galveston

University of Arizona Cancer Center at Dignity Health St. Joseph's, Phoenix